Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Ruben N. Karapetian"'
Autor:
Andrey A. Ivashchenko, Bogdan A. Zagribelnyy, Yan A. Ivanenkov, Ilya A. Ivashchenko, Ruben N. Karapetian, Dmitry V. Kravchenko, Nikolay P. Savchuk, Elena V. Yakubova, Alexandre V. Ivachtchenko
Publikováno v:
Molecules, Vol 27, Iss 15, p 4975 (2022)
The efficacy of aprotinin combinations with selected antiviral-drugs treatment of influenza virus and coronavirus (SARS-CoV-2) infection was studied in mice models of influenza pneumonia and COVID-19. The high efficacy of the combinations in reducing
Externí odkaz:
https://doaj.org/article/ccf7c0d76b51471eb97df4d970b00559
Autor:
Andrey A. Ivashchenko, Valeria N. Azarova, Alina N. Egorova, Ruben N. Karapetian, Dmitry V. Kravchenko, Natalia V. Krivonos, Vladimir G. Loginov, Stanislav V. Poyarkov, Elena A. Merkulova, Olga S. Rosinkova, Nikolay P. Savchuk, Mikhail A. Topr, Elena N. Simakina, Elena V. Yakubova, Alexandre V. Ivachtchenko
Publikováno v:
Viruses, Vol 13, Iss 7, p 1253 (2021)
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Externí odkaz:
https://doaj.org/article/bdadf2eb06b245cbb92ee84869032a4d
Autor:
Ivan N. Tyurenkov, Denis V. Kurkin, Dmitry A. Bakulin, Elena V. Volotova, Evgeny I. Morkovin, Mikhail A. Chafeev, Ruben N. Karapetian
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
This article is to highlight the chemical properties and primary pharmacology of novel GPR119 agonist ZB-16 and its analogs, which were rejected during the screening. Experiments were performed in vitro (specific activity, metabolism and cell toxicit
Externí odkaz:
https://doaj.org/article/5094ae50e2954506ba4953289aca47cf
Autor:
Andrei A Ivashchenko, Ekaterina A Glubokova, Vladimir A. Aladinskiy, Dmitry V. Kravchenko, Oleg D. Mitkin, Alexander V Nikitin, Irina N. Falynskova, Ruben N. Karapetian, Jeremy C. Jones, Irina A. Leneva, Elena A. Govorkova, Alexey A Ryakhovskiy, Alexandre V. Ivachtchenko, Stephan V Mochalov, Angela G. Koryakova
Publikováno v:
J Antimicrob Chemother
Background The development and clinical implementation of the cap-dependent endonuclease (CEN) inhibitor baloxavir marboxil was a breakthrough in influenza therapy, but it was associated with the emergence of drug-resistant variants. Objectives To de
Autor:
Stanislav V Poyarkov, Natalia V Krivonos, Elena N Simakina, Olga S Rosinkova, Elena A. Merkulova, Nikolay Filippovich Savchuk, Dmitry V. Kravchenko, Alina N. Egorova, Valeria N Azarova, Elena V Yakubova, Ruben N. Karapetian, Alexandre V. Ivachtchenko, Mikhail A Topr, Andrey Alexandrovich Ivashchenko, Vladimir G Loginov
Publikováno v:
Viruses, Vol 13, Iss 1253, p 1253 (2021)
Viruses
Viruses
COVID-19 is a contagious multisystem inflammatory disease caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydrox
Autor:
Elena A. Merkulova, Dmitriy S. Gorchakov, Oleg D. Mitkin, Nataliya A. Penchul, Alina N. Egorova, George E. Rupchev, Allan G. Beniashvily, Denis S. Burminskiy, Lala N. Kasimova, Ruben N. Karapetian, Natalia V. Vostokova, Lubov Y. Gluskina, Olga A. Bukhanovskaya, Margarita A. Morozova, Taissia A. Lepilkina, Dmitry V. Kravchenko, Andrey Alexandrovich Ivashchenko, Sergey S. Potanin, Alexandre V. Ivachtchenko
Publikováno v:
Journal of psychiatric research. 143
Generalized anxiety disorder (GAD) is associated with an imbalance in the functioning of the stimulating neurotransmitter systems in human's brain. We studied the safety and therapeutic efficacy of aviandr, the new noradrenergic and specific serotone
Autor:
Ruben N. Karapetian, Alexey A Ryakhovskiy, Alexander V Nikitin, Oleg D. Mitkin, Elena A. Govorkova, Angela G. Koryakova, Jeremy C. Jones, Irina A. Leneva, Ekaterina A Glubokova, Alexandre V. Ivachtchenko, Andrei A Ivashchenko, Dmitry V. Kravchenko, Vladimir A. Aladinskiy, Irina N. Falynskova
Publikováno v:
Journal of medicinal chemistry. 63(17)
4-Substituted 2,4-dioxobutanoic acids inhibit influenza virus cap-dependent endonuclease (CEN) activity. Baloxavir marboxil, 4, is approved for treating influenza virus infections. We describe here the synthesis and biological evaluation of active co
Autor:
Elena A Smolyarchuk, Natalia V. Vostokova, Andrew A. Blinow, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Nikolay Filippovich Savchuk, Tagir A. Sitdekov, Elena A. Merkulova, Kirill A. Dmitriev, Elena N Simakina, Elena P. Pavlikova, Valeria N Azarova, Natalia A. Papazova, Andrey Alexandrovich Ivashchenko, Alexandre V. Ivachtchenko, Alina N. Egorova, Nikita V. Lomakin, Dmitry V. Kravchenko, Alexey P. Ilin, Ivan G. Gordeev
Publikováno v:
Clinical Infectious Diseases
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Autor:
Ivan G. Gordeev, Andrey Alexandrovich Ivashchenko, Alexey P. Ilin, Dmitry V. Kravchenko, Nikolay Filippovich Savchuk, Kirill A. Dmitriev, Nikita V. Lomakin, Elena V Yakubova, Ruben N. Karapetian, Elena G. Tikhomolova, Elena N Simakina, Elena A. Merkulova, Natalia V. Vostokova, Natalia A. Papazova, Elena A Smolyarchuk, Alexandre V. Ivachtchenko, Andrew A. Blinow, Elena P. Pavlikova, Tagir A. Sitdekov, Alina N. Egorova, Valeria N Azarova
In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4c74b1b527e94b4d82f6b1475524f5
Autor:
Andrey V. Panchenko, Elena I. Fedoros, Sergey E. Pigarev, Dmitry I. Osolodkin, Alexey A. Orlov, Alexander Zherebker, Margarita L. Tyndyk, Mikhail Maydin, Ekaterina I. Izotova, Ekaterina A. Gubareva, Andrey I. Konstantinov, Evgeny N. Nikolaev, Ruben N. Karapetian, Vladimir N. Anisimov, Konstantin A. Krasnov, Irina V. Perminova
Publikováno v:
Oncotarget. 9:18578-18593
Identification of molecular targets and mechanism of action is always a challenge, in particular - for natural compounds due to inherent chemical complexity. BP-Cx-1 is a water-soluble modification of hydrolyzed lignin used as the platform for a port